Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...

Germany's Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed expectations. The life-sciences and chemical group said Thursday that it now ...